Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.73 Million EUR | -1368.52% |
| 2022 | -8.92 Million EUR | 93.54% |
| 2021 | -18.35 Million EUR | 10.88% |
| 2020 | -19.95 Million EUR | -2.42% |
| 2019 | -20.86 Million EUR | -252.61% |
| 2018 | 6.57 Million EUR | 275.18% |
| 2017 | -7.17 Million EUR | -5.93% |
| 2016 | -6.97 Million EUR | -154.68% |
| 2015 | 12.72 Million EUR | 178.94% |
| 2014 | -16.16 Million EUR | -325.64% |
| 2013 | -3.94 Million EUR | 30.96% |
| 2012 | -5.71 Million EUR | 7.12% |
| 2011 | -5.92 Million EUR | -38.08% |
| 2010 | -4.29 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -9.43 Million EUR | 0.0% |
| 2023 Q2 | -9.32 Million EUR | -160.31% |
| 2023 Q3 | -3.4 Million EUR | 63.48% |
| 2023 Q4 | -7.8 Million EUR | -129.07% |
| 2023 Q1 | -3.58 Million EUR | 65.68% |
| 2023 FY | - EUR | -1368.52% |
| 2022 Q1 | -2.45 Million EUR | 79.07% |
| 2022 Q2 | -7.81 Million EUR | -218.58% |
| 2022 Q3 | -3.71 Million EUR | 52.48% |
| 2022 Q4 | -10.43 Million EUR | -180.89% |
| 2022 FY | - EUR | 93.54% |
| 2021 Q1 | -4.58 Million EUR | 63.34% |
| 2021 Q3 | -4.59 Million EUR | 59.12% |
| 2021 Q4 | -11.72 Million EUR | -155.18% |
| 2021 FY | - EUR | 10.88% |
| 2021 Q2 | -11.23 Million EUR | -145.32% |
| 2020 FY | - EUR | -2.42% |
| 2020 Q1 | -5.23 Million EUR | 52.23% |
| 2020 Q2 | -13.44 Million EUR | -156.82% |
| 2020 Q4 | -12.49 Million EUR | -163.66% |
| 2020 Q3 | -4.73 Million EUR | 64.76% |
| 2019 Q2 | -15.88 Million EUR | -146.86% |
| 2019 FY | - EUR | -252.61% |
| 2019 Q4 | -10.96 Million EUR | -174.39% |
| 2019 Q3 | -3.99 Million EUR | 74.86% |
| 2019 Q1 | -6.43 Million EUR | -421.18% |
| 2018 Q1 | 7.41 Million EUR | 199.12% |
| 2018 Q4 | 2 Million EUR | 0.0% |
| 2018 FY | - EUR | 275.18% |
| 2018 Q3 | 2 Million EUR | -72.99% |
| 2018 Q2 | 7.41 Million EUR | 0.0% |
| 2017 FY | - EUR | -5.93% |
| 2017 Q4 | -7.48 Million EUR | 0.0% |
| 2017 Q3 | -7.48 Million EUR | -292.02% |
| 2017 Q2 | 3.89 Million EUR | 0.0% |
| 2017 Q1 | 3.89 Million EUR | 328.93% |
| 2016 Q2 | -1.93 Million EUR | 0.0% |
| 2016 Q3 | -1.7 Million EUR | 11.81% |
| 2016 Q1 | -1.93 Million EUR | -169.08% |
| 2016 Q4 | -1.7 Million EUR | 0.0% |
| 2016 FY | - EUR | -154.68% |
| 2015 Q4 | 2.79 Million EUR | 0.0% |
| 2015 FY | - EUR | 178.94% |
| 2015 Q3 | 2.79 Million EUR | 12.18% |
| 2015 Q2 | 2.49 Million EUR | 0.0% |
| 2015 Q1 | 2.49 Million EUR | 143.83% |
| 2014 Q1 | -2.69 Million EUR | -1217.81% |
| 2014 Q3 | -5.68 Million EUR | -110.52% |
| 2014 Q4 | -5.68 Million EUR | 0.0% |
| 2014 FY | - EUR | -325.64% |
| 2014 Q2 | -2.69 Million EUR | 0.0% |
| 2013 Q1 | -2.21 Million EUR | -7.95% |
| 2013 Q2 | -2.21 Million EUR | 0.0% |
| 2013 Q3 | 241.5 Thousand EUR | 110.92% |
| 2013 Q4 | 241.5 Thousand EUR | 0.0% |
| 2013 FY | - EUR | 30.96% |
| 2012 FY | - EUR | 7.12% |
| 2012 Q4 | -2.04 Million EUR | 0.0% |
| 2012 Q3 | -2.04 Million EUR | 0.0% |
| 2011 FY | - EUR | -38.08% |
| 2010 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -590.942% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 82.935% |
| Aelis Farma SA | -6.34 Million EUR | -258.153% |
| Biophytis S.A. | -13.8 Million EUR | -64.677% |
| Advicenne S.A. | -6.24 Million EUR | -264.061% |
| genOway Société anonyme | 6.35 Million EUR | 457.942% |
| IntegraGen SA | -52.5 Thousand EUR | -43196.574% |
| Medesis Pharma S.A. | -3.84 Million EUR | -491.227% |
| Neovacs S.A. | -8.44 Million EUR | -169.032% |
| NFL Biosciences SA | -4.04 Million EUR | -461.381% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 31441.514% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -691.097% |
| Sensorion SA | -22.31 Million EUR | -1.874% |
| Theranexus Société Anonyme | -7.38 Million EUR | -207.72% |
| TME Pharma N.V. | -5.07 Million EUR | -348.186% |
| Valbiotis SA | -6.95 Million EUR | -226.844% |
| TheraVet SA | -517.33 Thousand EUR | -4294.05% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -20.173% |
| argenx SE | -199.5 Million EUR | 88.606% |
| BioSenic S.A. | -6.79 Million EUR | -234.491% |
| Celyad Oncology SA | -7.76 Million EUR | -192.825% |
| DBV Technologies S.A. | -79.53 Million EUR | 71.417% |
| Galapagos NV | 51.03 Million EUR | 144.54% |
| Genfit S.A. | -28.05 Million EUR | 18.962% |
| GeNeuro SA | -14.31 Million EUR | -58.769% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -51.749% |
| Innate Pharma S.A. | -7.57 Million EUR | -199.974% |
| Inventiva S.A. | -101.84 Million EUR | 77.68% |
| MaaT Pharma SA | -19.74 Million EUR | -15.157% |
| MedinCell S.A. | -20.04 Million EUR | -13.399% |
| Nanobiotix S.A. | -34.01 Million EUR | 33.179% |
| Onward Medical N.V. | -35.23 Million EUR | 35.483% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -412.749% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 2.295% |
| Oxurion NV | -16.72 Million EUR | -35.884% |
| Pharming Group N.V. | 4.98 Million EUR | 556.377% |
| Poxel S.A. | -12.17 Million EUR | -86.649% |
| GenSight Biologics S.A. | -21.73 Million EUR | -4.611% |
| Transgene SA | -27.02 Million EUR | 15.882% |
| Financière de Tubize SA | 184.57 Thousand EUR | 12416.128% |
| UCB SA | 1.26 Billion EUR | 101.791% |
| Valneva SE | -64.51 Million EUR | 64.766% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 19.825% |